ArticleImmunity2022
The transcription factor IRF2 drives interferon-mediated CD8
Open access · greenAbstract read
In one paragraph
Article in Immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
9.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 125 citations in OpenAlex.
- Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026Review
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Proteomic Insights Into Human Induced Regulatory T Cells: The Role of LPXN and CD160 in Immune Suppression.Molecular & cellular proteomics : MCP · 2026Article
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.Cancer immunology research · 2026Article
- The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells.The Journal of experimental medicine · 2026Article
- Functional genomic analysis reveals HAVCR1 as the key regulator of 5q33.3 locus linked to hyperlipidemia.HGG advances · 2026Article
- Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026Review
- Context-dependent actions of STING pathway in colitis and associated colon cancer.Genes & diseases · 2026Review
- Transcription factors remodel tumor immune microenvironment by impacting multiple immune cells.Discover oncology · 2026Review
- Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy.Nature reviews. Immunology · 2026Review
- Striking the right balance with type I interferon signalling in cancer.Nature reviews. Cancer · 2026Review
- Deciphering the Transcription Factor-Dominated Ecosystem During Esophageal Squamous Cell Carcinoma Progression at the Single-Cell Level.International journal of molecular sciences · 2026Article
- Aberrant CD4bioRxiv : the preprint server for biology · 2026Article
- ZFP148 is a transcriptional repressor of cytolytic effector CD8Nature immunology · 2026Article
- Functional Type I and Type II interferon crosstalk restricts progenitor exhausted CD8 T cells through spatial exclusion and checkpoint enforcement.bioRxiv : the preprint server for biology · 2026Article
- TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer.Oncogene · 2026Article
- Regulators of CD8Nature reviews. Immunology · 2026Review
- Defining the cellular and molecular identities of histologic subtypes in lung adenocarcinoma.Experimental hematology & oncology · 2026Article
- IRF1 suppresses gastric tumorigenesis via dual PI3K/AKT-ERK pathway modulation and functional antagonism of oncogenic MX2.Cellular oncology (Dordrecht, Netherlands) · 2026Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors at 5 institutions in 2 countries.
Sabelo LukhelePrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada. Electronic address: sabelo.m.lukhele@gmail.com.
Diala Abd RabboPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
Mengdi GuoPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada; Department of Immunology, University of Toronto, Toronto, ON, M5S 1A8 Canada.
Jian ShenBlood Research Institute, Versiti Wisconsin, Milwaukee, WI 53226, USA; Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Heidi J ElsaesserPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
Rene QuevedoPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
Madeleine CarewPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
Ramy GadallaPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
Laura M SnellDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Lawanya MaheshPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
M Teresa CiudadPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
Bryan E SnowPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
Annick You-TenPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
Jillian HaightPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
Andrew WakehamPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada.
Pamela S OhashiPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada; Department of Immunology, University of Toronto, Toronto, ON, M5S 1A8 Canada.
Tak W MakPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada; Department of Immunology, University of Toronto, Toronto, ON, M5S 1A8 Canada.
Weiguo CuiBlood Research Institute, Versiti Wisconsin, Milwaukee, WI 53226, USA; Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Tracy L McGahaPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada; Department of Immunology, University of Toronto, Toronto, ON, M5S 1A8 Canada.
David G BrooksPrincess Margaret Cancer Center, University Health Network, Toronto, ON, M5G 2M9 Canada; Department of Immunology, University of Toronto, Toronto, ON, M5S 1A8 Canada. Electronic address: dbrooks@uhnresearch.ca.
University Health Network · CAPrincess Margaret Cancer Centre · CAUniversity of Toronto · CAVersiti Blood Center of Wisconsin · USIndiana University School of Medicine
Funding
Unfolded Protein Response and Autophagy in T Helper Cell Effector FunctionP20GM121176 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Monica Rosas Lemus · 2017 to 2026
$24.9MMechanisms of Viral PersistenceR01AI085043 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BROOKS, DAVID G · 2010 to 2023
$4.5MPhenotypic, Functional and Transcriptional Heterogeneity in T Cell ExhaustionR01AI148403 · NIAID · VERSITI WISCONSIN, INC. · PI WEIGUO CUI · 2020 to 2026
$3.1MMechanistic investigations of microbiome-driven aryl hydrocarbon receptor activity and macrophage function in pancreatic cancer.R01CA255670 · NCI · UNIVERSITY HEALTH NETWORK · PI MCGAHA, TRACY L · 2021 to 2025
$1.8MNCI NIH HHS R01 CA255670NIAID NIH HHS R01 AI085043NIAID NIH HHS R01 AI148403NIGMS NIH HHS P20 GM121176
Abstract
Type I and II interferons (IFNs) stimulate pro-inflammatory programs that are critical for immune activation, but also induce immune-suppressive feedback circuits that impede control of cancer growth. Here, we sought to determine how these opposing programs are differentially induced. We demonstrated that the transcription factor interferon regulatory factor 2 (IRF2) was expressed by many immune cells in the tumor in response to sustained IFN signaling. CD8
Indexed as
Interferon Type INeoplasmsCD8-Positive T-LymphocytesHumansInterferon Regulatory Factor-2T-Cell ExhaustionTranscription FactorsInterferon Regulatory Factor-2Interferon Type IIRF2 protein, humanTranscription Factorsadoptive cell transfercancerCD8(+) T cellsCyTOFimmunotherapyinterferon gammainterferon regulatory factor 2IRF2T cell exhaustiontype I interferon
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.